Skip to main content
. Author manuscript; available in PMC: 2012 Dec 13.
Published in final edited form as: Cancer Cell. 2011 Dec 1;20(6):701–714. doi: 10.1016/j.ccr.2011.11.002

Figure 7. VCAM-1 upregulation is dependent on NFκB activity.

Figure 7

(A) Dose-dependent inhibition of VCAM-1 expression by NFκB pathway inhibitors MG132 and helenalin as detected by western blot. (B) Inhibition of VCAM-1 expression by ectopic IκBαM expression as detected by western blot. (C) Differential abundance of nuclear RelA and cytoplasmic IκBα in SCP6 and VCAM-1+ PD cells as detected by western blot. (D) EMSA showing stronger band shift in PD1 and PD2D compared with SCP6. Wild type competitive probe (wt) and inhibitors MG132 and helenalin, but not mutated competitive probe (mut), blocked radioactive NFκB-specific probe binding. See also Figure S6.